Open AccessEffects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
Author(s) -
О. Н. Ткачева,
Ткачева Ольга Николаевна,
Irina Mikhailovovikova,
Новикова Ирина Михайловна,
Н. В. Шарашкина,
Шарашкина Наталья Викторовна,
Khyadi Magometovna Torshkhoeva,
Торшхоева Хяди Магометовна,
Н. К. Рунихина,
Рунихина Надежда Константиновна
Publication year - 2010
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-6014
Subject(s) - fenofibrate , medicine , dyslipidemia , diabetes mellitus , type 2 diabetes mellitus , glycated hemoglobin , diabetic neuropathy , peripheral neuropathy , lipid profile , complication , type 2 diabetes , endocrinology
Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy,it suggests the possibility to treat this disorder with fenofibrate.Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensiveand glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when thesought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability;QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound.